Alexandria Pharmaceuticals results, Q3 2025
Net profit, assets, equity and cash flow for Q3 2025, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit53.59 millionEGP · −75.3% vs the same period a year earlier
Shareholders' equity994 millionEGP · +25.1% vs the same period a year earlier
In short
- Alexandria Pharmaceuticals's net profit for Q3 2025 was about 53.59 million EGP, down −75.3% from 217 million EGP in Q3 2024.
Key lines against the same period a year earlier
This periodQ3 2024Change
Net profit53.59 million217 million−75.3%
Gross profit98.72 million613 million−83.9%
Total assets—1.24 billion—
Total liabilities—446 million—
Shareholders' equity994 million795 million+25.1%
Total liabilities and equity1.53 billion1.24 billion+23.0%
Operating cash flow—190 million—
Investing cash flow—-48.33 million—
Financing cash flow—-82 million—
Net change in cash—59.3 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy